Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Alpelisib Plus Endocrine Therapy Yields Similar PFS Benefits in Subgroup Analysis of PIK3CA-Mutated, HR+ Breast Cancer

May 6th 2022, 7:09pm

ESMO Breast Cancer Virtual Meeting

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

Trastuzumab Deruxtecan Maintains QOL and Global Health Status in HER2+ Metastatic Breast Cancer

May 6th 2022, 4:00pm

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.

Sacituzumab Govitecan Maintains Clinical Benefit Across HER2 Expressions in TNBC

May 5th 2022, 7:00pm

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.

Maintained Survival Benefit Supports Frontline Ribociclib/Fulvestrant Combo in Advanced HR+ Breast Cancer

May 5th 2022, 4:16pm

ESMO Breast Cancer Virtual Meeting

The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022, 7:00pm

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

Addition of Ublituximab/Umbralisib to Ibrutinib Produces High uMRD Rate in CLL

May 2nd 2022, 6:00pm

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)

JSP191 Plus Fludarabine and Low-Dose Irradiation Produces Promising Early Data in MDS/AML

April 27th 2022, 6:47pm

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

COVID-19 Vaccine Elicits Varied Immune Responses in cGVHD

April 27th 2022, 4:46pm

Transplantation and Cellular Therapy Meetings

Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population

Matched Sibling Donor Transplant Shows Improved OS at 2 Years in Relapsed/Refractory ALL

April 26th 2022, 4:58pm

Transplantation and Cellular Therapy Meetings

Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.

Iomab-B Yields Beneficial Rates of HCT in Relapsed/Refractory AML

April 26th 2022, 3:43pm

The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.

Itolizumab Generates Rapid Responses, Lowers Surface CD6 Levels in aGVHD

April 25th 2022, 8:23pm

Transplantation and Cellular Therapy Meetings

Itolizumab decreased levels of cell surface CD6 and increased soluble CD6 in serum in patients with acute graft-vs-host-disease.

Ruxolitinib Could Prevent Serious GVHD Following Allogeneic HCT

April 25th 2022, 7:28pm

Transplantation and Cellular Therapy Meetings

The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022, 6:25pm

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies

April 25th 2022, 6:05pm

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD

April 25th 2022, 6:00pm

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022, 5:27pm

Transplantation and Cellular Therapy Meetings

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL

April 25th 2022, 5:00pm

The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022, 2:27pm

Transplantation and Cellular Therapy Meetings

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma

April 25th 2022, 2:00pm

Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.

Frontline Axi-cel Elicits Rapid, Durable Responses in High-Risk Large B-Cell Lymphoma

April 24th 2022, 11:01pm

Transplantation and Cellular Therapy Meetings

The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.